Patient-friendly, non-technical summary of research papers

January 2026 Research Update

This report covers research on Cold agglutinin disease published in PubMed in January 2026. For other months, see all research updates.

Last update: July 2, 2026

At a glance

Rituximab and steroids

Rituximab plus steroids was followed by improved anemia and kidneys.

Trigger treatment

After treating the illness, blood cell clumping gradually cleared.

Blood count accuracy

White blood cell clumping can distort blood count results.

Illness-linked clumping

This month included two single-patient reports where CAD-like clumping appeared during other immune or infection-related illnesses. In both, clumping improved after treating the broader condition, and careful testing helped interpret blood counts.

Overview

This month’s published research was limited to two single-patient reports. Both described cold agglutinin disease (cold-related blood cell clumping) showing up during other immune or infection-related illnesses.

One report described an adult who had autoimmune conditions and also developed a complement-related kidney disease. Testing found a monoclonal IgM-kappa protein and a kidney biopsy with C3-dominant deposits. Treatment with rituximab (a B-cell targeted medicine) plus glucocorticoids was followed by improvement in anemia and kidney findings, with sustained remission reported.

The second report involved a 6-year-old boy with Mycoplasma-associated Kawasaki disease who developed secondary cold agglutinin disease. Treatment for Kawasaki disease was followed by symptom resolution without heart involvement. Neutrophil (a type of white blood cell) clumping cleared in about 1 week, and red blood cell clumping cleared in about 4 weeks as Mycoplasma antibody levels declined.

Taken together, these reports mainly add practical context. They highlight that the same lab finding can appear in different settings, and that careful testing can matter because clumping can affect how blood counts look.

Get the monthly update by email

Subscribe here to receive an email when a new monthly cold agglutinin disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month added two reminders that cold agglutinin disease (CAD) can show up in very different clinical situations, and that the same lab finding (blood cell clumping at cold temperatures) can have different causes and consequences. In these reports, CAD appeared alongside an immune-related kidney disease in an adult and alongside an infection-triggered inflammatory illness in a child, and both improved as the broader condition was treated. Because both reports describe single patients, they mainly help illustrate what CAD can look like rather than proving what will happen for others.

In one report, an adult with rheumatoid arthritis and Sjogren's syndrome developed CAD together with C3 glomerulonephritis, a kidney condition linked to complement (a part of the immune system). Testing found a monoclonal IgM-kappa protein and high cold agglutinin levels, and a kidney biopsy showed C3-dominant deposits; there was no clear cancer found on imaging and bone marrow evaluation. Treatment with rituximab (a B-cell targeted medicine) plus glucocorticoids was followed by prompt improvement in anemia and kidney findings, with sustained remission of both problems.

In the other report, a 6-year-old boy with Mycoplasma-associated Kawasaki disease had secondary cold agglutinin disease with clumping affecting both red blood cells and neutrophils (a type of white blood cell). After IVIG and aspirin for Kawasaki disease, the child improved without heart involvement; neutrophil clumping cleared in about 1 week and red blood cell clumping cleared in about 4 weeks as Mycoplasma antibody levels declined. The report also noted that white blood cell clumping can confuse blood count results, which is important for interpreting lab tests during illness.

For patients and caregivers, these reports mainly add context rather than changing care now: they show that CAD-like findings can appear with autoimmune disease, kidney inflammation tied to complement, or infections, and that sorting out the full cause may require more than a single blood test. They also underline that improvement in CAD signs can happen when the broader immune or infectious trigger is addressed, but single-patient experiences cannot predict results for everyone. What remains uncertain is how often these combinations occur and which treatments work best across different people, because larger studies were not reported in this month of evidence.

Limitations

All findings came from two single-patient reports, so they do not predict typical outcomes.
The reports covered unusual settings, so results may not apply to most people with cold agglutinin disease.
This month did not include larger studies to clarify how often these combinations occur or which treatments work best.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.